Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Short-term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-receptor Blocking Agents.

NCT00219388 is registered in ClinicalTrials.gov with Orion Corporation, Orion Pharma as lead sponsor.

NCT NCT00219388
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00219388 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Short-term Intravenous Treatment With Simdax® Versus Dobutrex® in Decompensated Heart Failure Patients Treated With Beta-receptor Blocking Agents.
Lead sponsor
Orion Corporation, Orion Pharma
Phase
Phase 4
Overall status
Completed
Start date
November 30, 2002
Completion date
April 30, 2005
Enrollment
60
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

heart failure